Vivani Medical
VANI
Market cap $63.5M

1.15 USD

-0.03

2.54%

At close Oct 7, 4:00 PM EDT

After hours

1.15

+0.00

0.00%

1 day

-2.54%

5 days

-1.71%

1 month

-3.36%

3 months

-8.73%

6 months

-47.25%

Year to date

10.58%

1 year

15.00%

5 years

-72.22%

About: Vivani Medical Inc is a preclinical-stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division.

Employees: 37

Healthcare Electromedical & Electrotherapeutic Apparatus

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

12% more funds holding

Funds holding: 25 [Q1] → 28 (+3) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 7

0.8% less ownership

Funds ownership: 11.16% [Q1] → 10.36% (-0.8%) [Q2]

32% less call options, than puts

Call options by funds: $97K | Put options by funds: $142K

37% less capital invested

Capital invested by funds: $11.4M [Q1] → $7.18M (-$4.17M) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for VANI.

See Analyst Rankings

Financial journalist opinion

Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced that the Bellberry Human Research Ethics Committee (“HREC”) has approved and the Therapeutic Goods Administration (“TGA”) in Australia has formally acknowledged a first in human clinical trial of the Company's miniature, subdermal GLP-1 (exenatide) implant in obese and overweight subjects. T.

Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that it will present at the Emerging Growth Conference on September 25, 2024. Vivani invites individual and institutional investors as well as advisors and analysts to attend its interactive presentation at the Emerging Growth Conference. This live, interactive online event will give e.

Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024

Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug implants, today reported positive preclinical liver fat results with its exenatide implant. “The reduction in liver fat observed preclinically with our miniature, subdermal exenatide implant, provides further support that the NanoPortal™ implant technology continues to hold great potential as a highly d.

Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant

Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug implants, today announced its plans to participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York, New York. Vivani's Chief Executive Officer, Adam Mendelsohn, Ph.D., will host one-on-one meetings with investors at the Conference in addition.

Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-acting drug implants, today reported financial results for the second quarter ended June 30, 2024, and provided a business update. Vivani's Chief Executive Officer Adam Mendelsohn, Ph.D., stated, “During the second quarter we achieved significant progress toward advancing the development of our proprietary, GLP-1 implants for obesity and ch.

Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results

Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, long-term drug implants, today announced that it expects to initiate the first clinical study in the NPM-115 program in the fourth quarter of 2024 in Australia, pending regulatory clearance in that country. The NPM-115 clinical program will evaluate the investigational 6-month GLP-1 implant for chronic weight management in patients who are.

Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115

Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, long-term drug implants, today announced the U.S. Food and Drug Administration has cleared the Investigational New Drug Application (“IND”) and lifted the clinical hold on NPM-119 to allow initiation of LIBERATE-1™, a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of NPM-119 (exenatide), the Company's miniat.

Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant

Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset NPM-115 for chronic weight management in obese or overweight human patients with one or more risk factors, today announced the publication of positive proof-of-concept weight loss data with OKV-119, a miniature, subdermal, exenatide drug implant designed to treat feline obesity and diabetes, in th.

Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant

VANI Stock Earnings: Vivani Medical Meets EPS for Q1 2024

Vivani Medical (NASDAQ: VANI ) just reported results for the first quarter of 2024. Vivani Medical reported earnings per share of -12 cents.

VANI Stock Earnings: Vivani Medical Meets EPS for Q1 2024

Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset NPM-115 for chronic weight management in obese or overweight patients with one or more risk factors, today reported financial results for the first quarter ended March 31, 2024, and provided a business update. Adam Mendelsohn, Ph.D., Vivani's Chief Executive Officer, stated, “Since pivoting to pri.

Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results

See News Rankings

Charts implemented using Lightweight Charts™